Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr 8;7(6):1149-1152.
doi: 10.1016/j.ekir.2022.04.003. eCollection 2022 Jun.

Chimeric Antigen Receptor Regulatory T Cell in Transplantation: The Future of Cell Therapy?

Caroline Lamarche  1 , Jonathan S Maltzman  2   3
Affiliations
Editorial

Chimeric Antigen Receptor Regulatory T Cell in Transplantation: The Future of Cell Therapy?

Caroline Lamarche et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the proposed therapy. HLA-A∗02–negative kidney transplant recipient enrolled to receive a living HLA-A∗02–positive kidney will be recruited in the STEADFAST trial. Tregs will be isolated from the recipient before transplant and genetically modified to express an HLA-A∗02 CAR. They will then be expanded and cryopreserved. Patients will receive a thymoglobulin induction as well with corticosteroids, tacrolimus, and MPA/MMF. Prednisone will be tapered off, and MPA/MMF tapering will be attempted in patients who received the cell therapy. HLA-A∗02 CAR Tregs will be infused 2 to 3 months after transplant. Patients will have protocol biopsies 16 and 36 weeks after transplant. Created with BioRender. CAR, chimeric antigen receptor; HLA, human leukocyte antigen; MMF, mycophenolate mofetil; MPA, mycophenolic acid; Treg, regulatory T cell.
See this image and copyright information in PMC

Comment on

References

    1. Schreeb K., Culme-Seymour E., Ridha E., et al. Study design: Human leukocyte antigen class I molecule A∗02-chimeric antigen receptor regulatory T cells in renal transplantation. Kidney Int Rep. 2022;7:1258–1267. - PMC - PubMed
    1. Dawson N.A., Lamarche C., Hoeppli R.E., et al. Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells. JCI Insight. 2019;4 doi: 10.1172/jci.insight.123672. - DOI - PMC - PubMed
    1. Roemhild A., Otto N.M., Moll G., et al. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. BMJ. 2020;371:m3734. doi: 10.1136/bmj.m3734. - DOI - PMC - PubMed
    1. Leclerc S., Lamarche C. Cellular therapies in kidney transplantation. Curr Opin Nephrol Hypertens. 2021;30:584–592. doi: 10.1097/MNH.0000000000000737. - DOI - PubMed
    1. Lamarche C., Levings M.K. Guiding regulatory T cells to the allograft. Curr Opin Organ Transplant. 2018;23:106–113. doi: 10.1097/MOT.0000000000000483. - DOI - PubMed

Publication types

LinkOut - more resources